Table 1 Key information of the EMPACT-MI trial [60]
From: CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
EMPACT-MI [60] | |
|---|---|
Class & cardiovascular (CV) outcomes | Effect of empagliflozin vs placebo (95% CI)* |
Primary endpoint | |
Composite of first HHF and death from any cause | 0.90 (0.76 to 1.06)§¥ |
Key secondary endpoints | |
Total no. of HHF or death from any cause | 0.87 (0.68 to 1.10)# |
Total no. of nonelective CV hospitalizations or death from any cause | 0.92 (0.78 to 1.07)# |
Total no. of nonelective hospitalizations for any cause or death from any causes | 0.87 (0.77 to 1.0)# |
Total no. of hospitalizations for MI or death from any cause | 1.06 (0.83 to 1.35)# |
Other secondary endpoints of interest | |
CV death | 1.03 (0.81 to 1.31)§ |
Total no. of HHF | 0.67 (0.5 to 0.89)# |